Navigation Links
ViroPharma Incorporated Reports Second Quarter 2009 Financial Results
Date:7/29/2009

31, 2008. The six month increase is primarily the result of net sales, offset by our repurchase of $45 million principal amount of our senior convertible notes. Cash flow provided by operating activities for the six months ended June 30, 2009 was $15.9 million.

Looking ahead in 2009

ViroPharma is revising its guidance for the year 2009. The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties. For a discussion of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below.

For the year 2009, ViroPharma expects the following:

  • Net Cinryze sales are expected to be $80 to $95 million.

  • Research and development (R&D) and selling, general and administrative (SG&A) expenses, including the impact of SFAS 123R, are expected to be $135 to $145 million, which includes approximately $18 million of maribavir-related expenses. SFAS 123R expenses are expected to be between $11 and $13 million.

The company is providing Cinryze net sales guidance and withdrawing Vancocin net sales guidance to align the company's guidance with its growth driver and in light of the August 4, 2009 FDA advisory committee regarding proposed bioequivalence recommendations for Vancocin.

Conference Call and Webcast

ViroPharma is hosting a live teleconference and webcast with senior management to discuss the financial announcement, guidance, and other business results on July 29, 2009 at 9:00 a.m. Eastern Time. To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international). After placing the call, please tell the operator you wish
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
2. ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
3. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
4. ViroPharma to Present at Two May Healthcare Conferences
5. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
6. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
7. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
8. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
9. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. ViroPharma Provides Update on Vancocin(R)
11. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... “Many people become overwhelmed by the ... issues and phone calls with insurance companies,” The Jones ... their free eBook on pedestrian and bicycle accidents ... and bicycle auto accident claims assures the injured individual ... professionally handling their case while they focus on recovering. ...
(Date:12/26/2014)... PA (PRWEB) December 26, 2014 Pentec ... Work in the state of Pennsylvania for 2014. The ... first statewide programs of its kind in the country. ... Foundation, the Pennsylvania Department of Community and Economic Development, ... Resource Management and the Central Penn Business Journal. ...
(Date:12/26/2014)... 26, 2014 Parker & Sons, ... best in heating, cooling and plumbing contractor services ... emergency services in 2014 with regard to air-conditioning ... Arizona is known for its incredibly hot summers. ... the intricacies and details of a wide variety ...
(Date:12/25/2014)... 2014 This is a professional and ... Sterilizers industry with a focus on the Chinese market. ... of the Sterilizers manufacturers and is a valuable source ... in the industry. This report provides a basic overview ... technology. In this part, the report presents the company ...
(Date:12/25/2014)... 2014 The report “Nintedanib (Colorectal ... focuses on the current treatment landscape, unmet needs, ... cancer market. Stivarga is a drug which is ... cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), an ... refractory CRC in the US, Europe, and Japan. ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
... workers increased more for small businesses than for large ones ... a significant number of small employers to abandon the benefit, ... , Small businesses (those with 25 or fewer employees) saw ... percent during the study period -- significantly more than the ...
... at Ralphs Pharmacies Throughout Southern California, LOS ANGELES, ... pharmacy customers generic drugs for $4 per prescription at,its ... apply to hundreds of generic drugs prescribed for,30-day supplies ... stores,throughout Southern California. A list of the participating pharmacies ...
... with Visit from Legendary Recording Artist Chaka Khan, ... California Science,Center welcomed the 1-millionth visitor to BODY ... has been a record-breaking run for BODY WORLDS,at ... Grammy,Award-winning recording artist Chaka Khan and a group ...
... between father,s, but not mother,s, weight and elevated enzymes ... fathers had early-onset obesity are at increased risk for ... U.S. study. , Researchers evaluated 1,732 children, average age ... long-term study of families in Framingham, Mass. The researchers ...
... Ky., April 3, 2008 Targeted mass,media ... high,sensation-seeking, impulsive decision-making young adults to adopt ... by the Department of,Communication at the University ... of Mental Health., Past public health ...
... 2008 Facial trauma,is a too frequent occurrence ... Carolyn McCarthy (D-N.Y.) hopes to raise,awareness of this ... (H. Res. 1062) to designate April 2008 as ... ), An estimated 5 million teeth are ...
Cached Medicine News:Health News:Study finds economic burden of health insurance increasing for small employers 2Health News:Ralphs Introduces $4 Generic Drugs 2Health News:California Science Center Welcomes 1-Millionth BODY WORLDS Visitor 2Health News:Dads' Early-Onset Obesity Linked to Liver Disease in Kids 2Health News:Study Finds Mass Media Campaigns Alone Can Effectively Reduce High-Risk Sexual Behavior Among Impulsive, Sensation-Seeking Young Adults 2Health News:Study Finds Mass Media Campaigns Alone Can Effectively Reduce High-Risk Sexual Behavior Among Impulsive, Sensation-Seeking Young Adults 3Health News:Oral and Maxillofacial Surgeons Raise Awareness About the Importance of Facial Protection 2
(Date:12/24/2014)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), ... unaudited preliminary financial results for the first quarter ... 2015 Ended September 30, 2014 Financial Highlights: ... million in 1Q14 with gross margins improved to ...
(Date:12/24/2014)... 2014  Conkwest, Inc., the Natural Killer Cell ... Killer (NK) cell-line platform, Neukoplast® (NK-92™) as an ... , NantWorks founder, physician scientist and biotechnology entrepreneur, ... approximately $48 million of the Company,s Class A ... will be named Co-Chairman of the Conkwest Board ...
(Date:12/24/2014)... SCHOFIELD, Wis. , Dec. 23, 2014 ... and marketer of over-the-counter (OTC) medicinal and healthcare products, ... production of MigraPure® H, a hemp-based, advanced headache relief ... marijuana dispensaries in Colorado , ... . With the MigraPure H Advanced ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... Ingelheim Pharmaceuticals, Inc. (BIPI) today announced plans to ... the safety and pharmacokinetics of dabigatran etexilate in ... 12-week study will compare three doses of dabigatran ... to warfarin in patients with both aortic valve ...
... politicians, patients and physicians gathered on the grounds of ... last week to celebrate the inauguration of Central America,s ... Quemados y Cirugia Pediatrica Ruth Paz. The ceremony was ... in Central America. The facility,s establishment was made possible ...
Cached Medicine Technology:Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 2Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 4Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 5Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 6Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 7Carolinas HealthCare System (CHS) Contributes to First Children's Burn Hospital in Central America 2Carolinas HealthCare System (CHS) Contributes to First Children's Burn Hospital in Central America 3
Integrated electronics, three-chip CCD camera with PAL and NTSC output at 750 lines, RGB-video. 44mm x 49mm x 75mm, 180 grams....
Large image and wide-angle design....
High intensity halogen lamp with built-in, switchable spare. Optical light concentrator to optimize existing light energy....
PDA application listing specific ICD-9 coding listed in new Medicare National Coverage Determinations....
Medicine Products: